Annual Current Liabilities
$3.78 M
-$3.70 M-49.51%
31 December 2023
Summary:
ReShape Lifesciences annual total current liabilities is currently $3.78 million, with the most recent change of -$3.70 million (-49.51%) on 31 December 2023. During the last 3 years, it has fallen by -$7.83 million (-67.45%). RSLS annual current liabilities is now -67.45% below its all-time high of $11.61 million, reached on 31 December 2020.RSLS Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Current Liabilities
$4.03 M
+$824.00 K+25.74%
30 September 2024
Summary:
ReShape Lifesciences quarterly total current liabilities is currently $4.03 million, with the most recent change of +$824.00 thousand (+25.74%) on 30 September 2024. Over the past year, it has dropped by -$444.00 thousand (-9.94%). RSLS quarterly current liabilities is now -93.35% below its all-time high of $60.50 million, reached on 30 June 2021.RSLS Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RSLS Current Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -49.5% | -9.9% |
| 3 y3 years | -67.5% | -61.1% |
| 5 y5 years | -54.8% | -65.6% |
RSLS Current Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -67.5% | at low | -61.1% | +25.7% |
| 5 y | 5 years | -67.5% | at low | -93.3% | +25.7% |
| alltime | all time | -67.5% | +68.5% | -93.3% | +79.5% |
ReShape Lifesciences Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $4.03 M(+25.7%) |
| June 2024 | - | $3.20 M(-9.0%) |
| Mar 2024 | - | $3.52 M(-6.8%) |
| Dec 2023 | $3.78 M(-49.5%) | $3.78 M(-15.5%) |
| Sept 2023 | - | $4.47 M(+1.5%) |
| June 2023 | - | $4.40 M(-42.1%) |
| Mar 2023 | - | $7.60 M(+1.6%) |
| Dec 2022 | $7.48 M(-0.7%) | $7.48 M(-0.4%) |
| Sept 2022 | - | $7.51 M(-18.2%) |
| June 2022 | - | $9.19 M(+12.7%) |
| Mar 2022 | - | $8.15 M(+8.2%) |
| Dec 2021 | $7.53 M(-35.1%) | $7.53 M(-27.1%) |
| Sept 2021 | - | $10.34 M(-82.9%) |
| June 2021 | - | $60.50 M(+179.7%) |
| Mar 2021 | - | $21.63 M(+86.4%) |
| Dec 2020 | $11.61 M(+11.7%) | $11.61 M(-18.7%) |
| Sept 2020 | - | $14.27 M(+15.6%) |
| June 2020 | - | $12.35 M(+14.7%) |
| Mar 2020 | - | $10.76 M(+3.6%) |
| Dec 2019 | $10.39 M(+24.2%) | $10.39 M(-11.3%) |
| Sept 2019 | - | $11.71 M(-3.7%) |
| June 2019 | - | $12.15 M(+2.6%) |
| Mar 2019 | - | $11.84 M(+41.6%) |
| Dec 2018 | $8.36 M(+18.7%) | $8.36 M(-5.4%) |
| Sept 2018 | - | $8.84 M(+1.6%) |
| June 2018 | - | $8.70 M(-0.9%) |
| Mar 2018 | - | $8.78 M(+24.7%) |
| Dec 2017 | $7.04 M(+73.4%) | $7.04 M(+70.4%) |
| Sept 2017 | - | $4.13 M(-8.3%) |
| June 2017 | - | $4.51 M(+21.3%) |
| Mar 2017 | - | $3.72 M(-8.5%) |
| Dec 2016 | $4.06 M(-9.4%) | $4.06 M(-49.0%) |
| Sept 2016 | - | $7.97 M(-22.6%) |
| June 2016 | - | $10.30 M(+9.8%) |
| Mar 2016 | - | $9.38 M(+109.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2015 | $4.49 M(-41.9%) | $4.49 M(+21.9%) |
| Sept 2015 | - | $3.68 M(-43.0%) |
| June 2015 | - | $6.45 M(-8.1%) |
| Mar 2015 | - | $7.02 M(-9.1%) |
| Dec 2014 | $7.72 M(-12.7%) | $7.72 M(-8.3%) |
| Sept 2014 | - | $8.42 M(-4.4%) |
| June 2014 | - | $8.80 M(+4.6%) |
| Mar 2014 | - | $8.42 M(-4.8%) |
| Dec 2013 | $8.84 M(+17.3%) | $8.84 M(+4.8%) |
| Sept 2013 | - | $8.43 M(+2.2%) |
| June 2013 | - | $8.26 M(-6.0%) |
| Mar 2013 | - | $8.79 M(+16.6%) |
| Dec 2012 | $7.54 M(-21.2%) | $7.54 M(+20.1%) |
| Sept 2012 | - | $6.28 M(+32.2%) |
| June 2012 | - | $4.75 M(-4.0%) |
| Mar 2012 | - | $4.94 M(-48.3%) |
| Dec 2011 | $9.56 M(+139.3%) | $9.56 M(+51.6%) |
| Sept 2011 | - | $6.31 M(+34.6%) |
| June 2011 | - | $4.69 M(+18.4%) |
| Mar 2011 | - | $3.96 M(-0.9%) |
| Dec 2010 | $4.00 M(-36.4%) | $4.00 M(-18.8%) |
| Sept 2010 | - | $4.92 M(+24.6%) |
| June 2010 | - | $3.95 M(-40.5%) |
| Mar 2010 | - | $6.64 M(+5.7%) |
| Dec 2009 | $6.28 M(+6.8%) | $6.28 M(-43.3%) |
| Sept 2009 | - | $11.09 M(+5.7%) |
| June 2009 | - | $10.49 M(+57.7%) |
| Mar 2009 | - | $6.65 M(+13.1%) |
| Dec 2008 | $5.88 M(-24.2%) | $5.88 M(-40.1%) |
| Sept 2008 | - | $9.81 M(+5.1%) |
| June 2008 | - | $9.34 M(+23.8%) |
| Mar 2008 | - | $7.54 M(-2.7%) |
| Dec 2007 | $7.75 M(+54.0%) | $7.75 M(+18.8%) |
| Sept 2007 | - | $6.53 M(+29.6%) |
| Dec 2006 | $5.03 M(+124.5%) | $5.03 M(+124.5%) |
| Dec 2005 | $2.24 M | $2.24 M |
FAQ
- What is ReShape Lifesciences annual total current liabilities?
- What is the all time high annual current liabilities for ReShape Lifesciences?
- What is ReShape Lifesciences annual current liabilities year-on-year change?
- What is ReShape Lifesciences quarterly total current liabilities?
- What is the all time high quarterly current liabilities for ReShape Lifesciences?
- What is ReShape Lifesciences quarterly current liabilities year-on-year change?
What is ReShape Lifesciences annual total current liabilities?
The current annual current liabilities of RSLS is $3.78 M
What is the all time high annual current liabilities for ReShape Lifesciences?
ReShape Lifesciences all-time high annual total current liabilities is $11.61 M
What is ReShape Lifesciences annual current liabilities year-on-year change?
Over the past year, RSLS annual total current liabilities has changed by -$3.70 M (-49.51%)
What is ReShape Lifesciences quarterly total current liabilities?
The current quarterly current liabilities of RSLS is $4.03 M
What is the all time high quarterly current liabilities for ReShape Lifesciences?
ReShape Lifesciences all-time high quarterly total current liabilities is $60.50 M
What is ReShape Lifesciences quarterly current liabilities year-on-year change?
Over the past year, RSLS quarterly total current liabilities has changed by -$444.00 K (-9.94%)